Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 OVERALL — PALG ALL7  

CD20-positive Acute Lymphoblastic Leukemia Clinical Trial

Official title: Efficacy and Safety of Obinutuzumab Versus Rituximab in Combination With Chemotherapy for Adult Patients With Newly Diagnosed CD20-positive Acute Lymphoblastic Leukemia

Status Not yet recruiting

Clinical Trial Summary

A multicenter, prospective, randomized and controlled study to compare the efficacy and safety of obinutuzumab and rituximab in adult ALL patients with CD20 expression.Study population is 124 patients (62 in each study group).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

• NCT number: NCT04920968
• Study type: Interventional
• Source: Maria Sklodowska-Curie Institute - Oncology Center
• Contact: Sebastian Giebel, prof. dr n.med.
• Phone: 32 278 85 23
• Email: Sebastian.Giebel@io.gliwice.pl
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 30, 2021
• Completion date: December 31, 2024